Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non‐Hodgkin lymphomas: A phase IB/II study. Issue 1 (30th November 2021) - Phillips, Tycel; Brunvand, Mark; Chen, Andy I.; Essell, James; Chiappella, Annalisa; Diefenbach, Catherine; Cheng, Ji; Ramies, David; Hirata, Jamie; Morschhauser, Franck; Flinn, Ian W.